Company Sponsored Symposia
Sunday, 27 May 2018
| Company Sponsored Symposium (CSS 1) ALK 10:30 – 12:00, Hall 14b |
 |
Shaking the trees: introducing the tree SLIT-tablet for birch group allergy
Chairs: Lone Winther, Denmark
Natalija Novak, Germany
Birch group pollen allergy in Europe: understanding the burden
Erkka Valovirta, Finland
Finding the right dose: results from an environmental exposure chamber
Anne Marie Salapatek, Canada
Confirming efficacy beyond birch: results from the European phase III field trial
Tilo Biedermann, Germany
| Company Sponsored Symposium (CSS 2) Novartis Pharma AG 13:30 – 15:00, Hall 5 |
 |
Why asthma is still uncontrolled in the 21st century: insight, impact and improvement 
Chair: Marc Humbert, France
Welcome and introduction
Marc Humbert, France
Characteristics and challenges of uncontrolled asthma
Marc Humbert, France
Inflammatory mechanisms in asthma: targets to gain control
Oscar Palomares, Spain
The challenges of managing asthma patients who smoke
Ashley Woodcock, United Kingdom
Uncontrolled asthma and comorbid nasal polyps: exploring the link
Claus Bachert, Belgium
Uncontrolled paediatric asthma: additional treatment challenges?
Adnan Custovic, United Kingdom
Chair-facilitated panel discussion and audience Q&A
All faculty
| Company Sponsored Symposium (CSS 3) AstraZeneca PLC 15:30 – 17:00, Hall 14a |
 |
Optimising Management of Severe Eosinophilic Asthma: An Interactive Expert Discussion
Chair: Christian Taube, Germany
Pathophysiology and Diagnostic Considerations
Christian Taube, Germany
Emerging Data and New Therapeutic Options
Sameer Mathur, United States
Insights From Patient Cases
David Jackson, United Kingdom
Monday, 28 May 2018
| Company Sponsored Symposium (CSS 4) Mylan 10:45 – 12:15, Hall 14a |
 |
5 minutes to change AR patients’ lives
Chair: Ludger Klimek, Germany
Introduction
Ludger Klimek, Germany
The need for speed
Peter Hellings, Belgium
Breaking the 5 minute speed barrier
David Price, United Kingdom
ARIA phase 4: Fast track to change
Jean Bousquet, France
Conclusion and Closing
Ludger Klimek, Germany
| Company Sponsored Symposium (CSS 5) HAL Allergy 13:45 – 15:15, Hall 5 |
 |
Allergy in a changing world
Chairs: Ronald van Ree, The Netherlands
Dirk-Jan Opstelten, The Netherlands
Climate Change – its effect on the allergy epidemic
Jeroen Buters, Germany
Biologics versus AIT – who will win?
Nikos Papadopoulos, United Kingdom/Greece
AIT: fixing current and future needs
Moisés Antonio Calderón, United Kingdom
| Company Sponsored Symposium (CSS 6) Allergopharma GmbH & Co. KG 15:45 – 17:15, Hall 5 |
 |
Allergoids – ready for the future
Chairs: Carsten Schmidt-Weber, Germany
Petra Zieglmayer, Austria
Detouring AIT development: lessons learned
Jörg Kleine-Tebbe, Germany
House dust mite SCIT: focus on asthmatic patients
Marek Jutel, Poland
Short cuts in pollen SCIT: a step towards better patient care
Matthias Kopp, Germany
Tuesday, 29 May 2018
| Company Sponsored Symposium (CSS 7) Thermo Fisher Scientific 10:30 – 12:00, Hall 14b |
 |
Allergic Asthma – Prediction, Prognosis and Management
Chair: Adnan Custovic, United Kingdom
Welcome to symposium – Should allergic sensitisation be included in diagnostic algorithms for asthma?
Adnan Custovic, United Kingdom
The importance of IgE in asthma
Robert Lemanske, United States
Early prediction and prevention of allergy and asthma
Karin Lødrup Carlsen, Norway
Diagnosis of respiratory allergy and use of CRD in ASIT
Pascal Demoly, France
Closing remarks and future directions
Adnan Custovic, United Kingdom
| Company Sponsored Symposium (CSS 8) STALLERGENES GREER 13:30 – 15:00, Hall 14a |
 |
Are you concerned with your allergic patients’ disease evolution? Take a BREATH of Real World Evidence
Is it time to think bigger: how can Real World Evidence change the game?
Adam Fox, United Kingdom
What is the impact of AIT on the disease evolution of respiratory allergy patients?
· New results from a French study with AIT-tablets for grass pollen allergies.
Pascal Demoly, France
· New results from a German study with AIT for birch pollen allergies.
Stefan Zielen, Germany / Ulrich Wahn , Germany
Round-table discussion
Finding answers: how will new Real World Evidence influence clinical decision making?
Pascal Demoly, France; Adam Fox, United Kingdom; Ulrich Wahn, Germany; Stefan Zielen, Germany